U.S. FDA Approves First Therapeutic Indication for Revance's

- Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market.1


- Approval expands the DAXXIFY® label to include efficacy data over the 52-week ASPEN repeat dose clinical...
-Today at 08:04 am- MarketScreener

Related Keywords

China , United States , American , Americans , Markj Foley , Peter Mcallister , Association Of Academic Physiatrists Annual Meeting , Peptide Exchange Technology , Revance Therapeutics Inc , American Academy Of Physical Medicine , Securities Exchange , Nasdaq , Dystonia Medical Research Foundation , Drug Administration , Exchange Commission , England Institute For Neurology , Hint Inc , Viatris Inc , Linkedin , Revance Therapeutics , Chief Executive Officer Mark , New England Institute , Label Study , Boxed Warning , Distant Spread , Specific Populations , Prescribing Information , Relational Commerce , Shanghai Fosun Pharmaceutical , Resilient Hyaluronic Acid , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Cervical Dystonia , Medical Research , Injection Through Multiple Cycles , Multicenter Trial , American Academy , Physical Medicine , Rehabilitation Annual Meeting , Injection Over Successive Treatments , Adults With Isolated Cervical Dystonia , Academic Physiatrists Annual Meeting , Markets ,